Revvity Highlights AUTOCRYPT's Post-Quantum Cybersecurity Solution for the Automotive Industry
- AUTOCRYPT launches "AutoCrypt PKI-Vehicles," a post-quantum cybersecurity solution for automotive systems enhancing security standards.
- The solution utilizes the ML-DSA digital signature algorithm, aligning with NIST standards for post-quantum cryptography.
- AUTOCRYPT showcases its innovations at CES 2026, emphasizing leadership in quantum-safe cybersecurity and regulatory compliance.
AUTOCRYPT Unveils Advanced Post-Quantum Cybersecurity Solution for Automotive Industry
AUTOCRYPT, a leader in automotive cybersecurity, announces the launch of "AutoCrypt PKI-Vehicles," a cutting-edge Public Key Infrastructure (PKI) solution designed to enhance security for automotive systems. This innovative offering features the ML-DSA, a post-quantum digital signature algorithm that positions AUTOCRYPT as one of the pioneers in commercializing quantum-safe cryptographic solutions. The introduction of AutoCrypt PKI-Vehicles aligns with the National Institute of Standards and Technology (NIST) standards for post-quantum cryptography, reflecting a forward-thinking approach in a rapidly evolving industry.
As the automotive sector faces unprecedented challenges from advancements in quantum computing, AUTOCRYPT's initiative focuses on helping manufacturers and suppliers transition to post-quantum solutions while maintaining their existing infrastructures. CEO Seokwoo Lee emphasizes the necessity of this shift, asserting that it is vital for ensuring the cybersecurity of vehicles against emerging threats. By adopting these advanced cryptographic standards, AUTOCRYPT aims to safeguard the future of automotive security and provide peace of mind to stakeholders in the industry.
AUTOCRYPT’s commitment to fostering a secure transportation ecosystem is further highlighted by its participation in the upcoming 2026 Consumer Electronics Show (CES) in Las Vegas, where it will showcase AutoCrypt PKI-Vehicles alongside its award-winning AutoCrypt CSTP product. The CSTP solution aids automotive original equipment manufacturers (OEMs) and suppliers in complying with critical regulatory standards, such as ISO/SAE 21434, WP.29 UN R155, and CRA. This strategic product launch not only reinforces AUTOCRYPT's leadership in quantum-safe cybersecurity but also signals a new era of innovation within the automotive industry.
In addition to its groundbreaking PKI solution, AUTOCRYPT continues to provide integrated security software for in-vehicle systems and related communications. This focus on comprehensive cybersecurity solutions ensures that automotive players can navigate the complexities of modern threats effectively. The company’s participation at CES will offer manufacturers an opportunity to engage directly with AUTOCRYPT’s experts, paving the way for collaborative advancements in automotive cybersecurity.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…

